

AMG 487

Catalog No: tcsc2662



Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg

Size: 100mg



Specifications

CAS No:

473719-41-4

Formula:

$C_{32}H_{28}F_3N_5O_4$

Pathway:

GPCR/G Protein;Immunology/Inflammation

Target:

CXCR;CXCR

Purity / Grade:

>98%

Solubility:

DMSO : ≥ 41 mg/mL (67.93 mM)

Observed Molecular Weight:

603.59

Product Description


AMG 487 is an antagonist of the chemokine receptor **CXCR3**, which inhibits binding of 125 I-IP-10 and 125 I-ITAC to CXCR3 with **IC₅₀**

values of 8.0 and 8.2 nM, respectively.

IC₅₀ & Target: IC₅₀: 8.0 nM (¹²⁵I-IP-10 binding to CXCR3), 8.2 nM (¹²⁵I-ITAC binding to CXCR3)

In Vitro: AMG 487 inhibits CXCR3-mediated cell migration by the three CXCR3 chemokines (IP-10 IC₅₀=8 nM, ITAC IC₅₀=15 nM, and MIG IC₅₀=36 nM). Furthermore, AMG 487 inhibits calcium mobilization in response to ITAC (IC₅₀=5 nM)^[1]. AMG487 (1 μM) develops into fewer lung metastases, and the lungs are significantly smaller than vehicle-treated lungs^[2]. AMG487 abrogates proliferation/survival of C26 tumour cells^[3].

In Vivo: AMG 487 (0.03-10 mg/kg, s.c.) exhibits significant reduction in cellular infiltration into the lungs in a dose dependent manner^[1]. AMG487 (5 mg/kg, s.c., twice daily) develops fewer metastases than that in vehicle-treated mice^[2]. AMG487 (5 mg/kg, s.c.)-treated mice exhibits fewer pulmonary nodules than the control mice in both the models. AMG487 reduces the tumour volume^[3].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!